Literature DB >> 7949172

All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells.

T Koyama1, S Hirosawa, N Kawamata, S Tohda, N Aoki.   

Abstract

The expressions of thrombomodulin (TM) and tissue factor (TF) by all-trans retinoic acid (ATRA) were studied in human leukemic cell lines including NB4 (acute promyelocytic leukemia) and U937 (monoblastic leukemia). ATRA remarkably upregulated TM antigen expression in cell lysates as well as TM cofactor activity on the cell surfaces of NB4. The level of TM mRNA in NB4 cells was increased by ATRA. Inherently procoagulant NB4 cells contained markedly higher content of TF, which was efficiently reduced by ATRA. Modest increase of TM and decrease of TF were observed when NB4 cells were treated with dibutyryl cyclic adenosine monophosphate (dbcAMP). On the other hand, both ATRA and dbcAMP showed dramatic increase of TM antigen level and modest decrease of TF antigen in U937 cells. These results suggest that ATRA regulates expressions of TM and TF antigens and activity in NB4 and U937 cell lines, and provide evidence for a potential efficiency of ATRA as a preventive and therapeutic agent for disseminated intravascular coagulation in promyelocytic and monocytic leukemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949172

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.

Authors:  Maximilian Stahl; Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2019-12-16

Review 2.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

3.  Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.

Authors:  G X Cheng; X H Zhu; X Q Men; L Wang; Q H Huang; X L Jin; S M Xiong; J Zhu; W M Guo; J Q Chen; S F Xu; E So; L C Chan; S Waxman; A Zelent; G Q Chen; S Dong; J X Liu; S J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 4.  Acute promyelocytic leukaemia in the all trans retinoic acid era.

Authors:  T G DeLoughery; S H Goodnight
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

Review 5.  Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.

Authors:  Nicole M Kuderer; Thomas L Ortel; Charles W Francis
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

6.  Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Authors:  Anna Falanga; Laura Russo; Carmen J Tartari
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-12-21       Impact factor: 2.576

7.  Arsenic trioxide downregulates cancer procoagulant activity in MCF-7 and WM-115 cell lines in vitro.

Authors:  Ewelina A Hoffman; Katarzyna Gizelska; Marek Mirowski; Wojciech Mielicki
Journal:  Contemp Oncol (Pozn)       Date:  2015-05-13

8.  Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.

Authors:  Sylvie Dunoyer-Geindre; Anne-Sophie Rivier-Cordey; Olga Tsopra; Thomas Lecompte; Egbert K O Kruithof
Journal:  Ann Hematol       Date:  2017-03-25       Impact factor: 3.673

9.  Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia.

Authors:  Sarah Cristina Bassi; Eduardo Magalhães Rego
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 10.  Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.

Authors:  Guilherme Augusto Dos Santos; Lev Kats; Pier Paolo Pandolfi
Journal:  J Exp Med       Date:  2013-12-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.